US2022354882A1PendingUtilityA1

Treatment of myelosuppression

74
Assignee: CANTEX PHARMACEUTICALS INCPriority: May 9, 2012Filed: Dec 14, 2021Published: Nov 10, 2022
Est. expiryMay 9, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:Stephen Marcus
A61P 35/02A61N 5/00A61K 31/727A61K 45/06A61K 39/395A61P 7/00A61K 35/28A61P 7/04
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of attenuating a myelosuppressive side effect of a patient treatment regimen comprising:
 adjunctively administering a therapeutically effective amount of a PF4-interacting heparinoid to the patient.

Join the waitlist — get patent alerts

Track US2022354882A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.